Saturday March 24, 2018

Isabelle Dinoire,world’s first partial face transplant recipient dies due to cancer

49 year old, face transplant recipient dies in April after succumbing to cancer

Isabelle Dinoire, the woman who received the world's first partial face transplant with a new nose, chin and mouth, in an operation on Nov. 27, 2005 Source:VOA
  • Isabelle Dinoire succumbed to cancer at the Amiens University Hospital
  • French doctors had stunned the world 11 years back by announcing they had given Dinoire a donor’s nose, lips, chin and parts of her cheek.
  • It is not clear if her illness was related to the transplant.

A Frenchwoman who received the world’s first partial face transplant has died, 11 years after the surgery that opened the way for dozens of other transplants worldwide.

The Amiens University Hospital in northern France announced Tuesday that Isabelle Dinoire succumbed to cancer in April.

Her family wanted the 49-year-old’s death kept private.

Follow NewsGram on Twitter

The hospital did not release further details and it is not clear if her illness was related to the transplant.

But heavy use of immunosuppressant drugs had weakened her system.

Follow NewsGram on Facebook

In 2005, French doctors Bernard Devauchelle and Jean-Michel Dubernard stunned the world by announcing they had given Dinoire a donor’s nose, lips, chin and parts of her cheek. She had been disfigured in a dog attack.

Dinoire’s partial face transplant sparked worldwide controversy. Critics questioned the ethics and the long-term consequences of the operation. (VOA)

Click here for reuse options!
Copyright 2016 NewsGram

Next Story

A Protein That Can Stop Cancer?

The research showed that LHPP emerged as the top favourite. Pixabay

Researchers have discovered a protein that prevents the uncontrolled proliferation of cancer cells in the liver.

The anti-cancer protein, called LHPP, can also serve as a biomarker for the diagnosis and prognosis of liver cancer, said the study published in the journal Nature.

The incidence of liver cancer, also known as hepatocellular carcinoma, is usually diagnosed at a very late stage when the liver is already severely damaged and hence overall prognosis is poor.

ALSO READ: World Cancer Day special: Fight cancer with hope and positive attitude

The researchers believe that detection of the anti-cancer protein LHPP as a biomarker may allow clinicians to provide better treatment options.

“It is striking that LHPP is present in healthy tissue and completely absent in tumour tissue,” said first author Sravanth Hindupur from University of Basel in Switzerland. Pixabay


In the study conducted in a mouse model for hepatocellular carcinoma, the researchers analyzed a total of more than 4,000 proteins, comparing them in healthy and tumour tissue.

ALSO READ: How gut bacteria, broccoli can help keep colorectal cancer away

Re-introduction of the genetic information for LHPP by the researchers was found to prevent the formation of tumours and maintain liver function.

“Similar to the mouse model, we also saw a striking decrease in LHPP levels in tumours of patients with liver cancer,” Hindupur said. (IANS)

Next Story